Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Probiotics to reduce infections in care home residents, the PRINCESS trial

The PRINCESS trial will assess the efficacy and mechanisms of a nutritional intervention (daily probiotics) to enhance immune function and reduce infection in care home residents. This is anticipated to reduce antibiotic prescribing for common infectious diseases in a high-risk population.   

Background

Care home residents (CHR) are particularly vulnerable to common infectious diseases which are the commonest cause of hospitalisation in this group, and often result in lasting health decline. Frailty, atypical presentation and bacterial colonisation patterns lead to high antibiotic use. Reducing antibiotic prescribing in the expanding care home sector is central to the challenge of containing antimicrobial resistance (AMR) in UK.

The PRINCESS trial will assess the efficacy and mechanisms of a nutritional intervention (daily probiotics) to enhance immune function and reduce infection in care home residents. This is anticipated to reduce antibiotic prescribing for common infectious diseases in a high-risk population. Antibiotic prescribing directly correlates with resistance. Fewer antibiotics will reduce the driving influence on AMR and is expected to reduce the likelihood of subsequent resistant infection.  

Study Design: Double-blind placebo controlled trial
Sponsor: Cardiff University
Chief Investigator: Professor Chris Butler, University of Oxford
Contact Details: princess@phc.ox.ac.uk